Physician
Kahen and Kahen ., M.D. INC
Kahen and Kahen ., M.D. INC was paid $2.56M by Medicaid between Jan 2018 and Oct 2024, across 63 billing codes. Its largest line is 99204, doctor's office visit, new patient (more involved) — 16% of everything it billed.
33Billing provider infoKAHEN AND KAHEN ., M.D. INC
ARLETA, CA 91331
ARLETA, CA 91331
33aNPI1063961241assigned 09/28/2016
33bProvider typeObstetrics & Gynecology Physician
28Total paid$2.56M
24GClaims142,151
24DCodes billed63
24AFirst – last monthJan 2018 – Oct 2024
Compared with peers
Next to other Obstetrics & Gynecology Physician providers in California
Rank by total paid#54 of 791
Median peer was paid$67K
This provider vs. median38×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 3,747 | $142K | |
| 2019 | 5,930 | $79K | |
| 2020 | 14,565 | $233K | |
| 2021 | 28,826 | $621K | |
| 2022 | 49,288 | $961K | |
| 2023 | 24,837 | $384K | |
| 2024incomplete | 14,958 | $135K |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99204 | Doctor's office visit, new patient (more involved)Office or other outpatient visit for the evaluation and management of a new patient, moderate complexity | 16% | 12,462 | 11,850 | $418K |
| 87637 | Infectious agent detection by nucleic acid; SARS-CoV-2, influenza, and RSV | 13% | 3,596 | 3,199 | $322K |
| 99214 | Doctor's office visit, returning patient (more involved)Office or other outpatient visit for the evaluation and management of an established patient, moderate complexity | 10% | 19,234 | 15,626 | $259K |
| U0004 | 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc, making use of high throughput technologies as described by cms-2020-01-r | 8.5% | 6,350 | 5,262 | $218K |
| 99213 | Doctor's office visit, returning patient (routine)Office or other outpatient visit for the evaluation and management of an established patient, low complexity | 7.8% | 11,203 | 8,914 | $200K |
| U0002 | 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc | 7.8% | 7,886 | 7,024 | $199K |
| 0225U | 6.3% | 1,612 | 1,377 | $160K | |
| 87636 | Infectious agent detection by nucleic acid; SARS-CoV-2 and influenza virus types A and B | 5.7% | 2,231 | 1,831 | $146K |
| 99203 | Doctor's office visit, new patient (routine)Office or other outpatient visit for the evaluation and management of a new patient, low complexity | 4.6% | 1,310 | 1,216 | $118K |
| 0241U | Neonatal screening for hereditary disorders, genomic sequence analysis panel | 4.4% | 2,442 | 2,155 | $113K |
| 87428 | 2.7% | 2,282 | 1,801 | $70K | |
| 87811 | Infectious agent antigen detection by immunoassay; SARS-CoV-2 (COVID-19) | 2.7% | 3,021 | 2,691 | $69K |
51 more codes
| G2023 | Specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source | 2.4% | 7,117 | $62K |
| U0005 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2 | 1.9% | 5,531 | $48K |
| 99000 | 1.4% | 17,180 | $37K | |
| S9088 | Services provided in an urgent care center (list in addition to code for service) | 1.1% | 4,574 | $28K |
| 99072 | <1% | 15,374 | $12K | |
| 99211 | Office or other outpatient visit for the evaluation and management of an established patient, minimal severity | <1% | 1,353 | $12K |
| 91320 | <1% | 196 | $9K | |
| 0124A | <1% | 232 | $7K | |
| 99212 | Office or other outpatient visit for the evaluation and management of an established patient, straightforward | <1% | 410 | $6K |
| 90480 | <1% | 384 | $5K | |
| 0134A | <1% | 163 | $5K | |
| 91322 | <1% | 136 | $3K | |
| 99051 | <1% | 2,515 | $3K | |
| 81025 | <1% | 2,640 | $3K | |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | <1% | 394 | $3K |
| S9445 | Patient education, not otherwise classified, non-physician provider, individual, per session | <1% | 152 | $2K |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | <1% | 25 | $2K |
| 99215 | Doctor's office visit, returning patient (complex) | <1% | 90 | $2K |
| 90686 | <1% | 82 | $1K | |
| A4267 | Contraceptive supply, condom, male, each | <1% | 231 | $1K |
| 0004A | <1% | 96 | $1K | |
| 81000 | <1% | 910 | $1K | |
| 93000 | <1% | 204 | $1K | |
| 90756 | <1% | 48 | $939.13 | |
| 0002A | <1% | 241 | $866.39 | |
| 99205 | Prolong outpt/office vis | <1% | 27 | $809.49 |
| 0064A | <1% | 43 | $804.29 | |
| 0053A | <1% | 27 | $797.60 | |
| 36415 | Collection of venous blood by venipuncture | <1% | 2,340 | $578.06 |
| 90471 | Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine | <1% | 128 | $451.11 |
| 0001A | <1% | 218 | $450.00 | |
| 0072A | <1% | 64 | $438.18 | |
| 0054A | <1% | 12 | $380.64 | |
| 0071A | <1% | 70 | $369.38 | |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | <1% | 113 | $259.63 |
| 90688 | <1% | 14 | $221.06 | |
| 87804 | Infectious agent antigen detection by immunoassay; Influenza, each type | <1% | 86 | $210.33 |
| 99202 | Office or other outpatient visit for the evaluation and management of a new patient, straightforward | <1% | 24 | $180.41 |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | <1% | 56 | $120.42 |
| S9083 | Global fee urgent care centers | <1% | 225 | $105.34 |
| 99173 | <1% | 254 | $80.75 | |
| 81002 | <1% | 1,049 | $76.12 | |
| G0008 | Administration of influenza virus vaccine | <1% | 25 | $60.00 |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 13 | $24.94 |
| 88150 | <1% | 2,919 | $22.89 | |
| 82962 | <1% | 71 | $7.92 | |
| 99385 | 0% | 52 | $0.00 | |
| Q0091 | Screening papanicolaou smear; obtaining, preparing and conveyance of cervical or vaginal smear to laboratory | 0% | 301 | $0.00 |
| 99395 | Periodic comprehensive preventive medicine reevaluation, established patient, 18-39 years | 0% | 72 | $0.00 |
| 99199 | Unlisted special service, procedure or report | 0% | 29 | $0.00 |
| 99396 | Periodic comprehensive preventive medicine reevaluation, established patient, 40-64 years | 0% | 12 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialKAHEN, TANAZ (VICE PRESIDENT)
| Provider | Location | Paid |
|---|---|---|
| Tanaz Kahen MD INC | Tarzana, CA | $588.86 |
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.